New Drug Application (NDA)

Drafts an eCTD-compliant NDA demonstrating safety and efficacy for FDA submission under 21 CFR Part 314.

Prerequisites

Clinical trial data — Phase 1–3 protocols, CSRs, statistical analyses, patient demographics
CMC documentation — drug substance characterization, manufacturing process, batch records, stability data
Nonclinical study reports — pharmacology, toxicology (general, genetic, reproductive, carcinogenicity), safety pharmacology
PK/bioavailability data — human PK, special populations, DDI studies, exposure-response analyses
Regulatory correspondence — pre-IND/pre-NDA meeting minutes, special protocol assessments, FDA feedback
Proposed labeling drafts — if available
Patent and exclusivity information — patent numbers, expiration dates, exclusivity claims

Output Structure

Module 1: Administrative Information

| Element | Requirements | |---|---| | Cover letter | Sponsor details, application type, regulatory pathway, special designations (breakthrough, fast track, priority review, orphan) | | FDA Form 356h | User fee info, debarment certification, field copy designations | | Proposed names | Proprietary and established names | | Indication statement | Precise medical terminology, dosage form, route, strength(s) | | Regulatory strategy | Reference pre-submission meetings, SPAs, unmet medical need narrative |

Module 2: Summaries

2.5 Integrated Summary & Benefit-Risk

Pharmacological class, MOA, therapeutic rationale
Development program overview (nonclinical → Phase 1 → 2 → 3 logic)
Pivotal trial summaries: design, population, endpoints, results (point estimates, CIs, p-values)
Integrated safety: AE profile across program, SAEs, deaths, safety signals
Risk mitigation: labeling, REMS if applicable
Benefit-risk weighing per 21 CFR 314.50(c): efficacy magnitude vs. AE frequency/severity, disease seriousness, existing therapies

2.3 Quality Overall Summary (CMC)

| Area | Key Elements | |---|---| | Drug substance | Chemical name, structure (stereochemistry), MW, solubility, polymorphism, particle size | | Synthetic pathway | Starting materials, reagents, CPPs, in-process controls, impurity profile with qualification | | Drug product | Quantitative formulation, excipient justification, compatibility evidence | | Manufacturing | Flow diagrams, equipment specs, CPP ranges, process validation (≥3 batches) | | Analytical methods | Validated for identity, assay, impurities, dissolution, CU | | Stability | ICH Q1A (long-term, intermediate, accelerated), stability-indicating methods, trending | | Container closure | System compatibility; device components if applicable (specs, human factors) | | Compliance | 21 CFR Parts 210/211 (cGMP) |

2.4 Nonclinical Overview

| Study Type | Key Elements | |---|---| | Primary pharmacodynamics | In vitro binding/functional assays, in vivo disease models | | Secondary pharmacodynamics | Off-target activity screen | | Safety pharmacology | hERG, in vivo QT, respiratory, CNS | | PK (animal) | ADME across tox species, metabolite ID, cross-species comparison | | Acute toxicity | Dose-response, target organ ID | | Repeat-dose toxicity | Duration matching intended clinical use, recovery data | | Genetic toxicology | Ames, in vitro chromosomal aberration, in vivo micronucleus | | Carcinogenicity | Two species (if chronic use), adequate duration/power | | Reproductive toxicity | Fertility, embryo-fetal (two species), pre/postnatal development |

All studies GLP-compliant per ICH M3(R2). Bridge nonclinical findings to clinical: starting dose selection, monitoring parameters, contraindications.

2.7 Clinical Summary

Pharmacokinetics: ADME profile — absorption (food effect, bioavailability), distribution (Vd, protein binding), metabolism (CYP isoforms, DDI potential), elimination (clearance, t½). Special populations: renal (mild→ESRD), hepatic (Child-Pugh A/B/C), elderly, pediatric, pharmacogenomics. Bioequivalence bridging if formulation changed. Exposure-response analysis → dosing justification.

Clinical Efficacy: Phase 1 (safety, PK, dose range) → Phase 2 (dose-ranging, dose selection rationale) → Phase 3 pivotal trials. For each pivotal trial: design/randomization/blinding, population (I/E criteria), primary + secondary endpoints, statistical plan (sample size, missing data, multiplicity), results with CIs and p-values, clinical meaningfulness. Include cross-trial consistency, subgroup analyses (age, sex, race, severity), and failed/negative trial explanations. Follow ICH E3 for CSR format.

Integrated Safety: Database size (total exposed, patient-years) vs. FDA adequacy guidance. Common AEs by SOC/PT (MedDRA) with dose-response. SAE narratives with causality. Death narratives (investigator + sponsor causality). Discontinuation rates. Lab shifts, vitals, ECG/QTc. Class-specific topics: hepatotoxicity (Hy's Law), immunogenicity (ADA), hypersensitivity, CV events, malignancies. Signal detection via disproportionality analysis.

Proposed Labeling (Module 1)

Draft per Physician Labeling Rule (21 CFR 201.56–57):

| Section | Key Requirements | |---|---| | Highlights | ≤½ page; recent changes, indication, dosing, contraindications, warnings, AEs | | Indications & Usage | Precise population, condition, limitations | | Dosage & Administration | Dose selection, preparation, technique, adjustments | | Contraindications | Evidence-based; clear statements | | Warnings & Precautions | By clinical importance; boxed warning if warranted | | Adverse Reactions | Table format (incidence), SAE detail, discontinuation AEs | | Drug Interactions | Clinically significant; management recommendations | | Specific Populations | Pregnancy (registry if applicable), lactation, pediatric, geriatric | | Clinical Pharmacology | MOA, PK summary | | Clinical Studies | Designs + results supporting indication |

Include Medication Guide if serious public health concern; Instructions for Use if device component or complex administration.

Risk Management, Patent & Exclusivity, Environmental

REMS (if applicable): goals, ETASU, implementation system, assessment timetable
Patent: numbers, expiration dates, certifications; exclusivity claims (NCE 5 yr, orphan 7 yr, pediatric 6 mo)
Environmental: claim categorical exclusion under 21 CFR 25.31; calculate EIC (max daily dose × annual patient population → aquatic concentration < 1 ppb); full EA if threshold exceeded

eCTD Assembly Checklist

[ ] Module 1: Administrative, labeling, patent info
[ ] Module 2: Summaries (quality, nonclinical, clinical)
[ ] Module 3: Quality (CMC) full data
[ ] Module 4: Nonclinical study reports
[ ] Module 5: Clinical study reports
[ ] Cross-references and hyperlinks between modules
[ ] Consistent terminology throughout
[ ] Proper eCTD file naming and metadata
[ ] Gap analysis: flag missing data and strategic decision points

Guidelines

Trace conclusions to source data — never assert efficacy or safety without citing specific trial results or study findings
Anticipate FDA questions — proactively address data limitations, alternative interpretations, ambiguous precedents
Statistical rigor — include point estimates, CIs, p-values; distinguish statistical from clinical significance
Mark gaps explicitly — flag missing data with [DATA NEEDED: description]
Regulatory citations [VERIFY current versions]: 21 CFR Part 314, 21 CFR Parts 210/211, 21 CFR 201.56–57, 21 CFR 25.31/25.40, ICH Q1A, ICH E3, ICH M3(R2)
U.S. FDA jurisdiction only — do not extrapolate to EMA, PMDA, or other authorities unless instructed
Draft for sponsor review — mark areas requiring sponsor input, additional data, or strategic decisions before submission